Trial NCT00570258

View at ClinicalTrials.gov 
Org. Study IDs: 57485
Secondary IDs: UARK 2004-19

Last trial update was posted on 2021-03-30

MeSH Interventions

Erlotinib Hydrochloride Fulvestrant

MeSH Conditions

Breast Neoplasms

Other Conditions

Metastatic Breast Cancer

Stopping Reasons

FDA approved higher dose of study drug. Dose used in protocol lower than SOC - enrollment stopped, those on treatment were given option to opt out.

Limitations And Caveats

Early termination due to a change in drug FDA approval. Outcome measures not computed because data would not be statistically relevant.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID